tirzepatide compounders Compounded (GLP-1/GIP) Trimi GLP-1 Review 2026: What

Timing: Some medications are administered daily, while others may require weekly injections

It's biology protecting you from what it perceives as scarcity

So, your prescriber may recommend switching to a different medication that you may tolerate better

Tirzepatide vs Retatrutide Researchers frequently compare tirzepatide and retatrutide as the two leading compounds in next-generation metabolic peptide research: Tirzepatide dual GIP/GLP-1 agonist, FDA approved as Mounjaro/Zepbound, extensive Phase 3 data, ~20-22% weight reduction Retatrutide triple GIP/GLP-1/Glucagon agonist, Phase 3 ongoing, ~24% weight reduction in Phase 2, not yet approved The additional glucagon receptor activity in retatrutide is what differentiates the two it increases energy expenditure directly, which may explain the higher weight reduction observed in Phase 2 trials